Skip to main content
Figure 5 | Breast Cancer Research

Figure 5

From: Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients

Figure 5

Survival analysis for patients with CD8-Res and CD8-NR to Her-2 according the levels of immunosuppressive subtypes. Survival of non-metastatic patients with low levels (lower than median) (A) MDSC-1 and CD8+ T cell response to Her-2 had significantly a better survival (P = 0.01) compared to the patients with high (higher than or equal to median) levels of MDSC-1 and no CD8+ T cell response to Her-2 (n = 15). No differences were observed in case of (B) MDSC-2 for non-metastatic patients (n = 15). Survival for non-metastatic patients with CD8+ T cell response to Her-2 and low (lower than median) levels of (C) Tregs (n = 12), (D) activated Tregs (n = 12), (E) ratio of activated/resting Tregs (n = 12) and (F) CD4+/FoxP3+ T cells (n = 12) tended to have a better survival compared to the patients with no CD8+ T cell response to Her-2 and high (higher than or equal to median) levels of regulatory T cell subtypes. Her-2, human epidermal growth factor receptor 2; MDSC, myeloid-derived suppressor cells; Tregs, regulatory T cells.

Back to article page